A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Clinical trial NCT05652686 · RECRUITING

Trial details

NCT number: NCT05652686
Sponsor: Phanes Therapeutics
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)Neuroendocrine Carcinomas (NEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Start date: 2023-09-05
Primary completion: 2027-12-01
Enrollment: 203

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.